REVIEW ARTICLE

When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the ‘Australian guidelines for the management of cutaneous melanoma’

David E Gyorki,1,2 Andrew Barbour,3,4 Mark Hanikeri,5 Victoria Mar,6,7,8 Shahneen Sandhu9 and John F Thompson10,11,12

1Division of Cancer Surgery, Peter MacCallum Cancer Centre, 2Department of Surgery, University of Melbourne, Melbourne, Victoria, 3Upper Gastrointestinal and Soft Tissue Unit, Princess Alexandra Hospital, 4Surgical Oncology Laboratory, Discipline of Surgery, University of Queensland, Brisbane, Queensland, 5Western Australia Melanoma Advisory Service, Perth, Western Australia, 6Victorian Melanoma Service, Alfred Hospital, 7Department of Epidemiology and Preventive Medicine, Monash University, 8Skin and Cancer Foundation Inc., 9Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, 10Melanoma Institute Australia, Poche Centre, 11Discipline of Surgery, University of Sydney, and 12Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

ABSTRACT

A sentinel lymph node biopsy is a surgical staging procedure performed for patients with primary cutaneous melanoma who are clinically lymph-node negative to determine whether there is low volume nodal metastasis in the draining lymph node field. A systematic review was recently performed to update the Australian clinical practice guidelines for the diagnosis and management of melanoma, addressing the question, ‘When is a sentinel lymph node biopsy indicated?’ This article discusses the findings of the systematic review and the evidence base for the updated guidelines.

Key words: guidelines, melanoma, sentinel node biopsy.

INTRODUCTION

A sentinel lymph node biopsy (SLNB) is a surgical staging procedure performed for patients with primary cutaneous melanoma who are clinically lymph-node negative to determine whether there is low-volume nodal metastasis in the draining lymph node field. A sentinel lymph node (SLN) is one that receives direct lymphatic drainage from the site of the primary tumour. The evidence base for performing the SLNB procedure continues to accumulate. A systematic review was performed to update the ‘Australian clinical practice guidelines for the diagnosis and management of melanoma’. The new guidelines have now been published through an online wiki platform (http://wiki.cancer.org.au/australia/Guidelines:Melanoma). This manuscript details the findings of the systematic review and gives details of the new, evidence-based national guidelines on a SLNB.

SEARCH METHODOLOGY

The multidisciplinary Melanoma Guidelines Working Party devised the question, ‘When is a sentinel node biopsy indicated?’ and a literature search was performed following the protocol for guideline development of the

<table>
<thead>
<tr>
<th>Abbreviations</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLND</td>
<td>completion lymph node dissection</td>
</tr>
<tr>
<td>MSLT</td>
<td>Multicenter Selective Lymphadenectomy Trial</td>
</tr>
<tr>
<td>MSS</td>
<td>melanoma-specific survival</td>
</tr>
<tr>
<td>SLNB</td>
<td>sentinel lymph node biopsy</td>
</tr>
<tr>
<td>SLN</td>
<td>sentinel lymph node</td>
</tr>
</tbody>
</table>
Cancer Council Australia Cancer Guidelines Wiki. The guideline development process involved a thorough literature search using PubMed, EMBASE, Trip and Cochrane Databases using the terms ‘melanoma’ and ‘sentinel node biopsy’. The literature search undertaken by the German Dermatologic Cooperative Oncology Group to develop the German melanoma management guidelines, published in 2015, was used as a starting point. The extracted evidence was graded according to objective criteria.

SLNB FOR OPTIMAL STAGING

SLNB for intermediate thickness (T2 and T3) melanomas

The most important publication on SLNB in melanoma patients is the final report of the first Multicenter Selective Lymphadenectomy Trial (MSLT-1). This was a large international randomised controlled trial comparing wide excision of the primary melanoma and regional node observation with wide excision and an SLNB followed by immediate completion lymph node dissection (CLND) for patients found to have a positive SLN. Patients in the observation arm underwent therapeutic lymph node dissection if they developed clinical lymph node involvement during the course of the follow-up. The study included 1661 patients and the main study group included the 1347 patients with melanomas of Breslow thickness 1.2–3.5 mm (designated intermediate thickness melanomas for the purpose of this study).

In a multivariate analysis, the MSLT-1 study showed that the status of the SLN (positive or negative) was the most significant predictor of overall survival (OS) (hazard ratio [HR] for death = 5.09; 95% CI: 2.12–4.49; P < 0.001). The 10-year melanoma-specific survival (MSS) for SLN-positive patients was 62%, versus 85% for SLN-negative patients (level of evidence II). Many large retrospective studies have also demonstrated the pre-eminence of an SLNB in risk stratification, with all but one showing the status of the SLN to be the most significant predictor of MSS (HR 1.5–6.9).

SLNB for thin (T1) melanomas

Most patients diagnosed with melanoma have a thin primary tumour (T1) and as a result more deaths from melanoma occur in this group of patients than from thick tumours (>4 mm), even though the risk of death for individual patients with thicker primary melanomas is greater. Patients with primary melanomas 0.75–1 mm in thickness and another adverse pathological feature such as ulceration, an elevated mitotic rate (>1 per mm²), Clark's level 4 or 5 invasive or lymphovascular invasion have a greater than 5% risk of SLN involvement and should therefore be considered for an SLNB. The presence of SLN involvement in patients with thin primary melanomas is associated with significantly worse MSS.

© 2017 The Australasian College of Dermatologists

SLNB for thick (T4) melanoma

The prognostic stratification provided by an SLNB also extends to patients with thick (T4) primary melanomas. A recent meta-analysis of 2104 patients with T4 melanomas demonstrated a consistent pattern across all the included studies, with the status of the SLN representing the most important predictor of outcome and the HR for overall survival according to SLN status of 2.5 (95% CI: 1.95–2.71).

The role of an SLNB in optimally staging patients with clinically lymph node-negative melanoma has been recognised in the recently published American Joint Committee on Cancer Cancer Staging Manual, 8th edn. Patients with melanomas >1 mm (T2–4) can be designated N0 only if staged by an SLNB, while patients with a T2–4 melanoma who do not undergo an SLNB are designated nodal status unknown.

EFFECT OF SENTINEL NODE BIOPSY ON PATIENT SURVIVAL

The primary end-point of the MSLT-1 study was MSS. The final report showed a small but not statistically significant difference in MSS for patients with an intermediate-thickness melanoma (as defined for the study) between those in the SLNB group (10-year MSS 81%) compared with the observation group (10-year MSS 78%) (HR for death = 0.84; 95% CI: 0.64–1.09; P = 0.18) (level of evidence II). However, the rate of SLN-positivity was only 16%, which was lower than the rate that had been used for statistical modelling in the trial, and therefore it is possible that the study was underpowered for demonstrating the primary end-point.

A post-hoc latent subgroup analysis was performed using a new statistical technique in an attempt to estimate treatment effect for the subgroup of patients who were SLN positive (i.e. at baseline in the SLNB arm and those who developed clinically positive nodes during follow up in the observation arm and who would have been expected to be SLN-positive had an SLNB been performed). This analysis showed that patients with intermediate thickness melanomas and nodal metastasis had a 10-year MSS of 62% with CLND compared with 42% with observation (HR for death = 0.56; 95% CI: 0.57–0.84; P = 0.006). The results of MSLT-1 thus suggest that the early removal of tumour-bearing lymph nodes substantially improves MSS, although there is some controversy about the validity of comparing these two groups as it is not possible to prove that they represent the same patient populations.

MORBIDITY OF SLNB

SLNB is a day surgery procedure with low morbidity. Complications are mainly minor and self-limiting, with reported rates varying from 6 to 14% which is much lower than for CLND (after a positive SLNB) or therapeutic lymph node dissection for macroscopic nodal disease. Hospitals with a higher volume of SLNB procedures have lower complication rates.
MANAGEMENT IMPLICATIONS OF SENTINEL LYMPH NODE STATUS

Today the SLNB forms an important part of the multidisciplinary management of patients with primary melanoma. It is the best currently available test for risk stratification and therefore plays a key role in optimally staging patients with primary melanoma. As previously discussed, patients with a positive SLN are two- to threefold more likely to die from their disease and therefore should be considered for adjuvant systemic therapy. In Australia, the only adjuvant systemic therapy currently listed on the Pharmaceutical Benefits Scheme is interferon alpha 2b. However, the results of the recently published European Organisation for research and Treatment of Cancer 18071 trial comparing post-operative ipilimumab versus placebo for resected stage III melanoma demonstrated a significant OS benefit for adjuvant ipilimumab. This is the first study to show a survival benefit of checkpoint blockade immunotherapy in the adjuvant setting. The trial used a high dose (10 mg/kg) of ipilimumab and was associated with significant toxicity and therefore has not immediately changed practice in the Australian setting. However, it demonstrates the utility of this class of agent in the adjuvant setting. In the near future results will be available from a number of randomised controlled trials of other adjuvant therapies, following which adjuvant systemic treatment may become standard for patients with SLN-positive melanoma.

GUIDELINE RECOMMENDATIONS

The final evidence-based recommendation in the new ‘Australian guidelines for the management of melanoma’ for the question ‘When is a sentinel lymph node biopsy indicated?’ states:

Sentinel lymph node biopsy should be considered for all patients with melanoma greater than 1 mm in thickness and for patients with melanoma greater than 0.75 mm with other high-risk pathological features to provide optimal staging and prognostic information and to maximise management options for patients who are node positive.

This recommendation has been assigned a grade B (good) level of evidence, indicating an evidence base with a low risk of bias and with substantial clinical impact, generalisability and applicable to the Australian health-care context.

The previous ‘Clinical practice guidelines for the management of melanoma in Australia and New Zealand’, published in 2008,19 recommended only that patients with a melanoma greater than 1.0 mm in thickness ‘be given the opportunity to discuss sentinel lymph node biopsy’. With the rapid and dramatic progress in the management of patients with advanced melanoma in recent years, patients with an early clinical stage of disease should now be considered for an SLNB, a staging procedure that will optimally determine their prognosis and allow informed planning of management for their melanoma.

ACKNOWLEDGEMENTS

The authors thank Ms Jutta von Dincklage, Ms Lani Teddy and the staff at Cancer Council Australia for guidance and support. The Development of the new Australian Clinical Practice Guidelines for the Diagnosis and Management of Melanoma was funded by Cancer Council Australia and Melanoma Institute Australia, with additional support from the Skin Cancer College Australasia.

REFERENCES


© 2017 The Australasian College of Dermatologists